We have located links that may give you full text access.
MUC21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma.
Histopathology 2018 October 18
AIMS: The process of differential diagnosis between epithelioid mesothelioma and lung adenocarcinoma has been progressing; however, there are no absolute immunohistochemical markers to definitively diagnose epithelioid mesothelioma. The aim of this study was to search for a novel negative marker of epithelioid mesothelioma.
MATERIALS AND METHODS: We immunohistochemically studied the applicability of mucin 21 (MUC21), which was identified in our previous study, as a novel, negative diagnostic marker for epithelioid mesothelioma. Seventy epithelioid mesothelioma and 70 lung adenocarcinoma cases were investigated for the expression of MUC21, along with other previously reported markers, by immunohistochemistry.
RESULTS: MUC21 was expressed in only 2 of the 70 (3%) epithelioid mesothelioma cases, compared to 67 of the 70 (96%) lung adenocarcinoma cases. The sensitivity, specificity, and accuracy of negative MUC21 expression to differentiate epithelioid mesothelioma from lung adenocarcinoma were 97%, 96%, and 96%, respectively, which are similar to those of carcinoembryonic antigen and claudin-4, and better than those of thyroid transcription factor-1, napsin-A, and mucin 4.
CONCLUSION: MUC21 could be used as an additional, novel, negative immunohistochemical marker to differentiate mesothelioma from lung adenocarcinoma. This article is protected by copyright. All rights reserved.
MATERIALS AND METHODS: We immunohistochemically studied the applicability of mucin 21 (MUC21), which was identified in our previous study, as a novel, negative diagnostic marker for epithelioid mesothelioma. Seventy epithelioid mesothelioma and 70 lung adenocarcinoma cases were investigated for the expression of MUC21, along with other previously reported markers, by immunohistochemistry.
RESULTS: MUC21 was expressed in only 2 of the 70 (3%) epithelioid mesothelioma cases, compared to 67 of the 70 (96%) lung adenocarcinoma cases. The sensitivity, specificity, and accuracy of negative MUC21 expression to differentiate epithelioid mesothelioma from lung adenocarcinoma were 97%, 96%, and 96%, respectively, which are similar to those of carcinoembryonic antigen and claudin-4, and better than those of thyroid transcription factor-1, napsin-A, and mucin 4.
CONCLUSION: MUC21 could be used as an additional, novel, negative immunohistochemical marker to differentiate mesothelioma from lung adenocarcinoma. This article is protected by copyright. All rights reserved.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app